Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)

A Anna Li (Nuffield Department of Clinical Neurosciences, University of Oxford) W Wei-Neng Feng J Juan Li B Bing-Fei Xu J Jun Zhao (Department of Thoracic Oncology Beijing Cancer Hospital Beijing China) Y Yun Jia K Ke-Jing Tang Y Yong-Sheng Li C Cheng-Zhi Zhou Y Yun Fan (Zhejiang Cancer Hospital, Hangzhou, China) C Chong-Rui Xu Y Yue-Li Sun H Hua-Jun Chen H Hong-Hong Yan Z Zong-Kun Shi J Jin-Ji Yang

Article Details

Volume / Issue Vol. 17, Issue 1
Published January 13, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (16)

A

Anna Li

Nuffield Department of Clinical Neurosciences, University of Oxford

W

Wei-Neng Feng

J

Juan Li

B

Bing-Fei Xu

J

Jun Zhao

Department of Thoracic Oncology Beijing Cancer Hospital Beijing China

Y

Yun Jia

K

Ke-Jing Tang

Y

Yong-Sheng Li

C

Cheng-Zhi Zhou

Y

Yun Fan

Zhejiang Cancer Hospital, Hangzhou, China

C

Chong-Rui Xu

Y

Yue-Li Sun

H

Hua-Jun Chen

H

Hong-Hong Yan

Z

Zong-Kun Shi

J

Jin-Ji Yang